An FDA advisory panel voted narrowly on Thursday to recommend that compounding pharmacies be permitted to manufacture the synthetic peptides BPC-157 and KPV. The decision follows a two-day meeting in which the panel evaluated whether to increase access to these substances, which are currently unapproved by the FDA.
The recommendation marks a notable development for proponents of peptide therapy and Health Secretary Robert F. Kennedy Jr., who has advocated for broader availability of these treatments. The panel’s deliberations addressed a growing trend of Americans using synthetic peptides despite ongoing FDA warnings regarding their unproven clinical benefits and potential safety risks.
In-depth summary · AI, neutral